Image of Immunotherapy in Lung Cancer

LITERATURE

Immunotherapy in Lung Cancer


Lung cancer is the leading cause of cancer-related mortality in the United States.1 Non–small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer cases.2 Among patients with NSCLC, approximately 40% present with stage IV disease.
3 Although targeted therapy has been associated with a significant benefit in patients harboring aberrations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS1,4–6 these gene abnormalities are present in a small
percentage of patients.


Availability

REQJ700-01Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
Hematol Oncol Clin N Am 31 (2017) 131–141
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous